[의학신문·일간보사=김영주 기자]Cho Yong-joon, Chairman of the Korea Pharmaceutical Cooperative Association, succeeded in serving three consecutive years. Since he was elected as the 23rd chairman for a four-year term in 2013, he has been elected as the 24th and 25th chairman at the general meeting held on the 17th, and will serve as the chairman for 12 years until February 2024.
 |
| Chairman Cho Yong-joon of the Korea Pharmaceutical Cooperative Association, who was unanimously appointed for three consecutive years, gives a greeting from the general meeting. |
The association held the 57th regular general meeting face-to-face in the auditorium on the 4th floor of the Korea Pharmaceutical Bio Association at 2 pm on the 17th, as this general meeting is a general meeting of executive elections.
On this day, the general meeting, which was held amid thorough quarantine, unanimously reappointed the current chairman Yong-joon Cho (Vice-Chairman of Dong-gu Biopharmaceuticals), while executives such as directors and auditors were confirmed as originally planned.
On the board of directors, ▲ CEO Kim Woo-tae of Kuju Pharmaceutical ▲ Tae-hoon Nam, CEO of International Pharmaceuticals ▲ Seung-yeol Baek, CEO of Daewon Pharmaceuticals ▲ Yoon-woo Lee, CEO of Daewon Pharmaceuticals ▲ Representative of Kwa-jin Kim at Mothers Pharmaceuticals ▲ Seong-han Hong, CEO of BC World Pharmaceuticals ▲ Choong-hwan Lee of Samik Pharmaceuticals ▲ Byung-ki Lee, CEO of Shinshin Pharmaceuticals ▲ Representative Eojin of Ahn Kook Pharmaceuticals ▲ Lee Hang-gu, CEO of HLB Pharmaceutical ▲ Park Jae-hyeong, CEO of HLB Pharmaceutical ▲ Kim Kook-hyun, CEO of InistST ▲ Kim Dong-jin, CEO of Personnel ▲ Moon Seong-ho, CEO of Korea Pharmaceuticals ▲ Park Eun-hee, CEO of Korea Pharma ▲ Choi Yong-eun, CEO of Korea Pharmaceuticals ▲ Kim Seong-gyeom, CEO of Korea Hutex Pharmaceutical ▲ Kim Jung-jin, CEO of Hanlim Pharmaceutical ▲ Hanpoong Pharmaceutical CEO In-sik, etc., were appointed. In addition, ▲ Daewoo Pharmaceutical CEO Ji Yong-hoon ▲ Jinyang Pharmaceutical CEO Jae-joon Choi were elected.
During his six years in office, Chairman Cho Yong-joon has taken the lead in improving the system for the development of the small and medium-sized pharmaceutical industry, and has been evaluated as taking the lead in strengthening the internal and external status of the industry by acting as a vice chairman of the Small and Medium Business Administration.
In particular, Chairman Cho is evaluating that it has contributed to substantial management improvement of members. He has made a lot of contributions to the improvement of the management of members by preparing measures for inefficient quality management such as joint purchase of experimental equipment, establishment of an authorized testing center, and relief of the burden of quality management work. In recent years, small and medium-sized pharmaceutical companies have devised plans for logistics innovation and are pursuing mid- to long-term implementation plans.
On this day, the General Assembly also decided to revitalize organizations and functions, revitalize joint projects, and reinforce information business as major industries in 2021, while finalizing a new annual budget of 539 million won.
Meanwhile, in the first part of the event prior to the agenda deliberation, Chairman Yong-joon Cho said in an opening remark, “The pharmaceutical bio industry is a promising export business, and is facing an opportunity for sustainable growth to reduce public expectations, but the small and medium-sized pharmaceutical industry is pressured by stepped drugs to block the entry of late generics, raw material impurities. He said, “We are facing difficulties such as the burden of quality improvement costs due to detection,” he said. “We plan to make efforts to achieve rational system improvement by collecting opinions from union members related to the system, drawing common opinions, delivering them to the government, and persuading them.”
Hee-mok Won, chairman of the Korea Pharmaceutical Bio Association, said in a congratulatory remark, “The pharmaceutical bio industry is facing an opportunity to strive for future values in the expectations of the government and the people in situations such as Corona 19.” It is necessary to actively challenge the global advance through cooperation, etc.”
Meanwhile, the list of winners of the general meeting on this day is as follows. ▲Small and Medium Ventures Minister Award: Jinwoo Lee, Vice President of Pharma Korea, Jongmoon Kim, Vice President of Donggu Bio Pharmaceutical ▲Small and Medium Business Administration Award: Seongil Choi, General Manager of Kuju Pharmaceutical, Ilho Jung of Korea Hutex Pharmaceutical ▲Chairman of Korea International Pharmaceutical Cooperative Association Director Minji Heo.
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>